查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496008

全球乳癌診斷市場 - 2024 年至 2029 年預測

Global Breast Cancer Diagnosis Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 133 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022 年乳癌診斷市值為 48.59 億美元，預計複合年成長率為 7.92%，到 2029 年市場規模將達到 82.85 億美元。

乳癌被定義為乳房組織的惡性，已成為全世界女性的主要癌症。醫生會進行多項測試來診斷癌症的起始部位，並找出癌症是否擴散到身體的其他部位。預計乳癌市場在給定的預測期內將呈現強勁成長，這可歸因於全球乳癌盛行率的上升。

此外，世界各地的政府和組織正在實施各種舉措，以提高人們對乳癌的認知並支持早期診斷，預計這將在預測期內推動市場成長。此外，混合成像技術的引入等技術進步預計也將推動未來幾年的市場成長。

市場促進因素：

  • 全球乳癌發生率上升預計將推動市場發展。

世界各地的乳癌病例不斷增加，增加了對其診斷和治療的需求。據世界衛生組織稱，2020年將有230萬名女性被診斷出患有乳癌，導致68.5萬人死亡。此外，每年新患者數量超過了肺癌，佔全球所有癌症患者的11.7%。

世界癌症研究基金會和世界衛生組織表示，2008年至2020年間，全球乳癌發生率增加了20%，死亡率增加了14%。預計未來幾年乳癌病例也將急劇增加，這預計將推動預測期內乳癌診斷市場的成長。美國癌症協會估計，美國將診斷出 281,550 例新的女性侵襲性乳癌病例和 2,650 例男性新病例。此外，根據美國癌症協會的數據，預計 2021 年將有 44,000 人死亡，其中包括 43,600 名女性和 530 名男性。

  • 政府提高乳癌診斷率的措施導致市場成長激增。

世界各國政府都擔心乳癌的持續傳播，也會影響各國的經濟健康。因此，各國政府正在推出新舉措，透過提高人們對該疾病的認知並提供早期診斷援助來應對乳癌發病率上升的問題。

澳洲政府負責實施“澳洲乳房篩檢計劃”，這是澳洲政府與州和領地政府之間的聯合舉措。該計劃旨在及早診斷乳癌並降低乳癌發病率和死亡率。 2021年5月，澳洲政府累計聯邦預算超過1億美元用於乳癌和子宮頸癌篩檢計畫。

2021年2月，歐盟委員會宣布了歐洲戰勝癌症計劃，旨在改善歐盟（EU）的癌症預防、治療和護理。該計劃的四個關鍵行動領域之一是確保到 2025 年，90% 符合乳癌篩檢資格的歐盟人口（包括其他幾種癌症類型）都能接受乳癌篩檢，其目標包括：

世界各國政府也發起了各種其他舉措，預計將增加乳癌診斷，因此預計將在未來幾年推動市場成長。

北美地區佔據主要市場佔有率。

從地理位置來看，由於乳癌發生率高，北美地區預計將佔據較大的市場佔有率。根據世界衛生組織統計，北美年齡標準化（全球）發生率為每10萬人89.4例，僅次於澳洲和紐西蘭以及西歐。

此外，高度發展的醫療保健系統和民眾的高度意識是支持北美市場主導地位的其他一些重要因素。由於該地區乳癌發生率不斷上升，以及各國政府為提高意識和早期發現乳癌而採取的各種舉措，預計亞太地區的乳癌發生率將顯著成長。

主要進展

  • 2023 年 6 月 - 數位病理解決方案和臨床人工智慧應用領域的全球領導者 Paige 推出了擴展版 Paige Breast Suite。該套件包括 Paige Breast Detect、Paige Breast Neoplasm、Paige Breast Mitosis、Paige Breast Lymph Node 和 HER2Complete，旨在提高乳癌診斷的效率和可靠性。該套件還包括一個由人工智慧驅動的有絲分裂計數工具，這是乳癌診斷的關鍵組成部分。 Paige 乳房檢測和腫瘤允許病理學家優先考慮病例審查，並且達到臨床級別並符合監管標準。
  • 2023 年 5 月 - 輝瑞和賽默飛世爾科技合作，為 30 多個國家的肺癌和乳癌患者提供基於次世代定序(NGS) 的檢測。此次合作旨在提供更快的基因分析，幫助醫療保健專業人員為每位患者選擇正確的治療方法。 Thermo Fisher 將確定使用 NGS 技術的當地實驗室，並確保它們擁有必要的基礎設施、訓練有素的員工和品管措施。
  • 2023 年 5 月 - Hologic 讚揚了 USPSTF 近期的乳癌篩檢指南，並表示增加篩檢機會對於早期發現和挽救生命至關重要。該公司對建議從 40 歲開始進行篩檢的改變表示讚賞，因為大約 60,000 例乳癌是在 50 歲以下的女性中被診斷出來的。 Hologic 承認，黑人女性罹患進行性癌症的時間比白人女性年輕 40%，而且死於乳癌的可能性更高。
  • 2023 年 2 月 - HALO Precision Diagnostics 在其位於加州奇科的乳房護理中心推出了用於乳癌早期檢測的 HALO PathWay(TM)。這種創新方法使用先進的成像、基於人群的分析和基因檢測來提供個人化護理。它在美國尚屬首創，旨在透過在可以進行微創治療的第一或第二階段檢測疾病來拯救生命。 HALO 在南加州也擁有最先進的基因檢測實驗室。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球乳癌診斷市場：依診斷技術分類

  • 介紹
  • 影像
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 切片檢查
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 臨床檢查
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球乳癌診斷市場：依癌症類型分類

  • 介紹
  • BRCA 乳癌
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • ER & PR 乳癌
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • HER2 乳癌
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • EGFR突變檢測乳癌
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章全球乳癌診斷市場：依最終用戶分類

  • 介紹
  • 醫院和診所
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 癌症研究中心
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 診斷實驗室
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球乳癌診斷市場：按地區

  • 介紹
  • 北美洲
    • 透過診斷技術
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 透過診斷技術
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 透過診斷技術
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 透過診斷技術
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 透過診斷技術
    • 按癌症類型
    • 按最終用戶
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Abbott
  • Hologic Inc.
  • F. Hoffmann-La Roche Ltd
  • GE Healthcare
  • Thermo Fisher Scientific Inc.
  • Koninklijke Philips NV
  • Siemens AG
  • Fujifilm Holdings Corporation
  • Myriad Genetics
  • Carestream Health
簡介目錄
Product Code: KSI061611916

The global breast cancer diagnosis market is evaluated at US$4.859 billion for 2022 and is projected to grow at a CAGR of 7.92% to reach a market size of US$8.285 billion by 2029.

Breast cancer is defined as a malignant tumor formed in the tissues of the breast and has emerged as the leading cancer among women across the globe. The doctors carry out several tests to diagnose the site of initiation as well as to know if the cancer has metastasized to other body parts or not. The breast cancer market is expected to show robust growth during the given forecast period, which may be attributed to the rising prevalence of breast cancer across the globe.

Furthermore, various initiatives are being implemented by governments and organizations worldwide to spread awareness and assist in the early diagnosis of breast cancer, which is anticipated to propel the market's growth during the forecast period. Technological advancements, such as the introduction of hybrid imaging techniques, are also expected to augment the market's growth in the coming years.

Market Drivers:

  • The rising prevalence of breast cancer worldwide is anticipated to drive the market.

The cases of breast cancer have been increasing constantly all over the globe, which has led to an increased need for its diagnosis and treatment. According to the WHO, 2.3 million females were diagnosed with breast cancer in 2020, with the number of deaths accounting for 685 thousand. Furthermore, it has surpassed lung cancer in terms of the number of new cases per year and accounts for 11.7% of the total cancer cases worldwide.

The World Cancer Research Fund International and the WHO state that the incidence of breast cancer has increased by 20% globally between 2008 and 2020, while mortality has increased by 14%. The cases of breast cancer are projected to continue surging in the coming years as well, which is anticipated to propel the global breast cancer diagnosis market growth during the forecast period. The American Cancer Society estimates that the number of newly diagnosed cases of invasive breast cancer in the United States will be 281,550 in women, and 2,650 cases will be diagnosed among men. Furthermore, as per the American Cancer Society, an estimated death of 44,000 people, including 43,600 women and 530 men, is projected to occur in the year 2021.

  • Government initiatives for increasing breast cancer diagnosis pose to surge in the market growth.

The governments of countries around the world have been concerned regarding the continuous spread of breast cancer, which can hurt a country's economic condition as well. As a result, governments are launching new initiatives to tackle the rising incidence of breast cancer by increasing awareness and providing aid for early diagnosis.

The Australian government runs the "BreastScreen Australia Program", a joint initiative of the Australian and state and territory governments. The program aims to diagnose breast cancer at an early stage and consequently reduce illness and death from breast cancer. In May 2021, the Australian government announced that its federal budget would include more than $100 million for breast and cervical cancer screening programs.

In February 2021, the European Commission presented its "Europe's Beating Cancer Plan", which aims to improve cancer prevention, treatment, and care in the European Union. One of the four key action areas of the plan includes the target of ensuring that 90% of the EU population who qualify for breast cancer screenings, among a few other cancer types, are offered screening by 2025.

Various other initiatives are being launched by governments worldwide that are anticipated to increase the diagnosis of breast cancer and, hence, are projected to propel the market growth in the coming years.

The North American region holds a significant market share.

Geographically, the North American region is anticipated to hold a significant market share owing to its high incidence rate of breast cancer. According to the WHO, North America has an age-standardized (world) incidence rate of 89.4 per 100,000, which is only behind "Australia & New Zealand" and "Western Europe".

Furthermore, a highly developed healthcare system and high awareness among the population are some of the other prominent factors behind the market dominance in North America. The Asia-Pacific region is anticipated to witness substantial growth due to the rising incidences of breast cancer in the region, coupled with various initiatives implemented by the governments to spread awareness and for early detection of breast cancer.

Key Developments:

  • June 2023- Paige, a global leader in digital pathology solutions and clinical AI applications, launched its expanded Paige Breast Suite. The suite included Paige Breast Detect, Paige Breast Neoplasm, Paige Breast Mitosis, Paige Breast Lymph Node, and HER2Complete, designed to improve diagnostic efficiency and confidence in breast cancer diagnosis. The suite also includes an AI-powered tool for mitotic counting, a critical element of breast cancer diagnosis. Paige Breast Detect and Neoplasm enable pathologists to prioritize the review of cases and is a clinical-grade and meets regulatory standards.
  • May 2023- Pfizer and Thermo Fisher Scientific partnered to enhance local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in over 30 countries. The collaboration aims to provide faster gene analysis, enabling healthcare providers to select the right therapy for each patient. Thermo Fisher identify local labs using NGS technology and ensure they have the necessary infrastructure, trained staff, and quality control measures. Pfizer explore affordable patient access and raise healthcare provider awareness about advanced testing benefits.
  • May 2023- Hologic praised the USPSTF's recent breast cancer screening guidelines, stating that increasing access to screening is crucial for early detection and saving lives. The company commends the change, recommending women begin screening at age 40, as approximately 60,000 breast cancers are diagnosed in women under 50. Hologic acknowledges that Black women are 40% more likely to develop aggressive cancers at younger ages and die from breast cancer than white women.
  • February 2023- HALO Precision Diagnostics introduced the HALO PathWay(TM) for early breast cancer detection at its Chico, California Breast Care Center. This innovative approach uses advanced imaging, population-based analytics, and genetic testing to provide personalized care. The first of its kind in the US, it aims to save lives by detecting disease in stage 1 or 2 when minimally invasive therapies are available. HALO also has a state-of-the-art genetic testing laboratory in southern California.

Market Segmentation:

By Diagnostic Techniques

  • Imaging
  • Biopsy
  • Laboratory Tests

By Cancer Type

  • BRCA Breast Cancer
  • ER & PR Breast Cancer
  • HER 2 Breast Cancer
  • EGFR Mutation Test Breast Cancer
  • Others

By End-User

  • Hospitals and Clinics
  • Cancer Research Centers
  • Diagnostic Laboratories
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Belgium
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY DIAGNOSTIC TECHNIQUES

  • 5.1. Introduction
  • 5.2. Imaging
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Biopsy
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Laboratory Tests
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness

6. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY CANCER TYPE

  • 6.1. Introduction
  • 6.2. BRCA Breast Cancer
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. ER & PR Breast Cancer
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. HER 2 Breast Cancer
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. EGFR Mutation Test Breast Cancer
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals and Clinics
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Cancer Research Centers
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Diagnostic Laboratories
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL BREAST CANCER DIAGNOSIS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Diagnostic Techniques
    • 8.2.2. By Cancer Type
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Diagnostic Techniques
    • 8.3.2. By Cancer Type
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Diagnostic Techniques
    • 8.4.2. By Cancer Type
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. UK
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Italy
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Belgium
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
      • 8.4.4.6. Others
        • 8.4.4.6.1. Market Opportunities and Trends
        • 8.4.4.6.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Diagnostic Techniques
    • 8.5.2. By Cancer Type
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Diagnostic Techniques
    • 8.6.2. By Cancer Type
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. Japan
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. South Korea
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Taiwan
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Thailand
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Indonesia
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Australia
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects
      • 8.6.4.9. New Zealand
        • 8.6.4.9.1. Market Opportunities and Trends
        • 8.6.4.9.2. Growth Prospects
      • 8.6.4.10. Others
        • 8.6.4.10.1. Market Opportunities and Trends
        • 8.6.4.10.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Abbott
  • 10.2. Hologic Inc.
  • 10.3. F. Hoffmann-La Roche Ltd
  • 10.4. GE Healthcare
  • 10.5. Thermo Fisher Scientific Inc.
  • 10.6. Koninklijke Philips N.V.
  • 10.7. Siemens AG
  • 10.8. Fujifilm Holdings Corporation
  • 10.9. Myriad Genetics
  • 10.10. Carestream Health